Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology @Cosmo_Pharma #HealthCare #OTC #OTCMarkets #OTCStocks #Investing

Ad hoc announcement pursuant to Art. 53 LR EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET. Dublin, Ireland--(Newsfile Corp. - July 23, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today reported strong half-year results for 2025, underscoring the Company’s...


http://dlvr.it/TM42F9

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology

Hearts Connect along the Silk Road, International Voluntary Service Seminar Held in Nanjing #